Anti-HRAS Polyclonal Antibody

Catalog No.

PHB91001

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human HRAS (Phe82-Glu176).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

c-H-ras,GTPase HRas,H-Ras-1,p21ras,Transforming protein p21,Ha-Ras,HRAS1,HRAS

Purification

Purified by antigen affinity column.

Accession

P01112

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312., PMID:40304209

A Child with Cutaneous-Skeletal Hypophosphatemia Syndrome Caused by a Mosaic HRAS Mutation: Outcome of Treatment with Anti-FGF23 Antibody., PMID:40295341

RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs., PMID:39992626

Spitz Spindle Cell/Reed Nevus With SQSTM1 :: NTRK2 Fusion and Atypical Features in an Older Male Patient: A Case Report and Review of Literature., PMID:39980385

De novo design of Ras isoform selective binders., PMID:39975043

Elucidating the pharmacological foundations and mechanisms of the Sihai Shuyu formula in treating Graves' disease through integrated serum metabolomics and network pharmacology with molecular docking techniques., PMID:39950029

Burosumab Treatment in a Girl With Cutaneous Skeletal Hypophosphatemia Syndrome: 2-Year Follow-Up., PMID:39925163

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors., PMID:39914665

Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial., PMID:39446377

Detection and Quantitation of Endogenous Membrane-Bound RAS Proteins and KRAS Mutants in Cancer Cell Lines Using 1D-SDS-PAGE LC-MS2., PMID:39052226

Human BioMolecular Atlas Program (HuBMAP): 3D Human Reference Atlas Construction and Usage., PMID:38826261

Genetically Encoded Epoxide Warhead for Precise and Versatile Covalent Targeting of Proteins., PMID:38819260

Cytokine CCL9 Mediates Oncogenic KRAS-Induced Pancreatic Acinar-to-Ductal Metaplasia by Promoting Reactive Oxygen Species and Metalloproteinases., PMID:38731942

Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer., PMID:38612819

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer., PMID:38588697

K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3., PMID:38291468

Liquid Droplet-Mediated Formulation of Lipid Nanoparticles Encapsulating Immunoglobulin G for Cytosolic Delivery., PMID:38290425

Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers., PMID:38236605

Update on current diagnosis and management of anaplastic thyroid carcinoma., PMID:38179406

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma., PMID:38105998

Confirmation of canine acanthomatous ameloblastoma using RAS Q61R immunohistochemical staining of formalin-fixed paraffin-embedded tissues., PMID:37901104

Antibodies against endogenous retroviruses promote lung cancer immunotherapy., PMID:37046094

Adaptable, Turn-On Monobody (ATOM) Fluorescent Biosensors for Multiplexed Detection in Cells., PMID:37034669

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer., PMID:37020035

Simultaneous Administration of Bevacizumab with Bee-Pollen Extract-Loaded Hybrid Protein Hydrogel NPs Is a Promising Targeted Strategy against Cancer Cells., PMID:36834960

Rare molecular subtypes of lung cancer., PMID:36806787

Analysis of H-ras Mutations and Immunohistochemistry in Recurrence Cases of High-Grade Oral Squamous Cell Carcinoma., PMID:36374444

Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer., PMID:36100320

[The Effect of KRAS on Proliferation and Apoptosis of T-ALL Cell Lines]., PMID:35981360

Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer., PMID:35471938

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model., PMID:35210547

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia., PMID:35120522

Engineering a cell-penetrating hyperstable antibody scFv(Ras) - An extraordinary approach to cancer therapeutics., PMID:34738045

Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC)., PMID:34700281

Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model., PMID:34429319

The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice., PMID:34277420

Probing RAS Function with Monobodies., PMID:33977484

Validation of Isoform- and Mutation-Specific RAS Antibodies., PMID:33977472

Absolute Quantitation of GTPase Protein Abundance., PMID:33977471

NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility., PMID:33960437

RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480., PMID:33765976

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study., PMID:33753043

PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation., PMID:33681239

Transglutaminase-2, RNA-binding proteins and mitochondrial proteins selectively traffic to MDCK cell-derived microvesicles following H-Ras-induced epithelial-mesenchymal transition., PMID:33638284

Cross-reactivity of NRASQ61R antibody in a subset of Spitz nevi with 11p gain: a potential confounding factor in the era of pathway-based diagnostic approach., PMID:33636207

Enumeration, characterisation and clinicopathological significance of circulating tumour cells in patients with colorectal carcinoma., PMID:33610860

Cx43 phosphorylation sites regulate pancreatic cancer metastasis., PMID:33603164

Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody., PMID:33462327

Magnetic spatiotemporal control of SOS1 coupled nanoparticles for guided neurite growth in dopaminergic single cells., PMID:33384447

Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer., PMID:33162802

Document Download

Anti-HRAS Polyclonal Antibody.pdf